| Q45870380 | A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa a |
| Q44894913 | Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies |
| Q47324534 | Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding. |
| Q37550053 | Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs |
| Q35544621 | Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding |
| Q34294608 | Remodeling the blood coagulation cascade |
| Q34458071 | The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. |
| Q61405248 | The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis |
| Q45871588 | Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa |